This Dengvaxia market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historical period can be attributed to government health initiatives, increasing public health awareness, the rising demand for preventive measures, an uptick in travel-related dengue cases, and improvements in healthcare infrastructure.
The projected growth for the forecast period is driven by the rising frequency of dengue outbreaks, increased government funding, collaborations between public and private sectors, greater public awareness about dengue prevention, and further advancements in healthcare infrastructure. Key trends expected during this period include progress in vaccine technology, continuous research and development, innovations in vaccine delivery methods, the creation of new formulations, and improved vaccine storage and distribution techniques.
The increasing incidence of dengue is expected to drive the growth of the dengvaxia market. Dengue is a viral infection transmitted by Aedes mosquitoes, causing flu-like symptoms, intense pain, and, in severe cases, complications such as dengue hemorrhagic fever or dengue shock syndrome, which can be life-threatening. The rising prevalence of dengue is attributed to factors such as climate change, urbanization, increased travel, and the expansion of mosquito breeding grounds, leading to higher infection rates and an increased demand for prevention and treatment. Dengvaxia is an effective vaccine that prevents dengue by stimulating the immune system to produce protective responses against the virus, reducing the risk of infection and severe complications, and improving public health outcomes in endemic areas. For example, in June 2024, the Centers for Disease Control and Prevention (CDC) reported that the Americas had over 9.7 million dengue cases in 2024, double the 4.6 million cases in 2023. Puerto Rico declared a public health emergency with 1,498 cases, and 745 cases were reported among U.S. travelers. As a result, the high incidence of dengue is propelling the growth of the dengvaxia market.
The rise in international travel is expected to fuel the growth of the dengvaxia market. International travel, which includes tourism, business, and education, increases the risk of spreading infectious diseases such as dengue. This heightened risk drives the demand for preventive measures such as vaccines. Dengvaxia helps protect travelers from contracting dengue in endemic areas and reduces the risk of disease transmission across borders. For instance, in May 2024, the Office for National Statistics reported a significant increase in the number of international visits to the UK, rising from 31.2 million in 2022 to 38 million in 2023. As a result, the growth in international travel will contribute to the expansion of the dengvaxia market.
The rising healthcare expenditures are expected to further accelerate the growth of the dengvaxia market. Healthcare expenditures refer to the financial resources allocated by governments, private entities, or individuals for healthcare services, medical treatments, and health-related activities. The growth in healthcare expenditures is driven by factors such as the increasing demand for medical services, advancements in healthcare technology, and the rising prevalence of chronic diseases, leading to greater investment in healthcare infrastructure and treatments. The expenditure on Dengvaxia focuses on prevention, aiming to reduce the long-term costs of treating dengue and managing outbreaks. For example, in May 2024, the Office for National Statistics reported a 5.6% increase in nominal healthcare expenditure from 2022 to 2023, marking a significant acceleration compared to the 0.9% growth in 2022. Therefore, rising healthcare expenditures will further stimulate the growth of the dengvaxia market.
The key company operating in the dengvaxia market is Sanofi Pasteur Inc.
Asia-Pacific was the largest region in the dengvaxia market in 2024. Latin America is expected to be the fastest-growing region in the forecast period. The regions covered in dengvaxia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dengvaxia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Dengvaxia is a recombinant vaccine designed to protect against dengue fever, a viral disease transmitted by Aedes mosquitoes. It works by stimulating the immune system to generate a targeted response, preventing infection and reducing the risk of severe complications. This vaccine plays a key role in public health efforts in areas where dengue is endemic.
The main category of dengvaxia includes the vaccine itself and other related options. Dengvaxia is the first vaccine specifically developed to prevent dengue fever. It aims to provide immunity against the virus that causes the disease, helping to lessen the severity and frequency of dengue outbreaks. As an essential tool in regions prone to dengue, it has been used in various countries to protect at-risk populations. Dengvaxia is distributed through hospitals, clinics, and public health programs, and is administered for multiple purposes, such as preventing the disease in individuals with prior exposure, offering protection in high-risk areas, immunizing travelers, and supporting pediatric and adolescent vaccination.
The dengvaxia market research report is one of a series of new reports that provides dengvaxia market statistics, including dengvaxia industry global market size, regional shares, competitors with a dengvaxia market share, detailed dengvaxia market segments, market trends and opportunities, and any further data you may need to thrive in the dengvaxia industry. This dengvaxia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The dengvaxia market consists of sales of dengvaxia (CYD-TDV), disposable syringes and needles, pre-filled syringes of dengvaxia, and unit-dose packaging. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historical period can be attributed to government health initiatives, increasing public health awareness, the rising demand for preventive measures, an uptick in travel-related dengue cases, and improvements in healthcare infrastructure.
The projected growth for the forecast period is driven by the rising frequency of dengue outbreaks, increased government funding, collaborations between public and private sectors, greater public awareness about dengue prevention, and further advancements in healthcare infrastructure. Key trends expected during this period include progress in vaccine technology, continuous research and development, innovations in vaccine delivery methods, the creation of new formulations, and improved vaccine storage and distribution techniques.
The increasing incidence of dengue is expected to drive the growth of the dengvaxia market. Dengue is a viral infection transmitted by Aedes mosquitoes, causing flu-like symptoms, intense pain, and, in severe cases, complications such as dengue hemorrhagic fever or dengue shock syndrome, which can be life-threatening. The rising prevalence of dengue is attributed to factors such as climate change, urbanization, increased travel, and the expansion of mosquito breeding grounds, leading to higher infection rates and an increased demand for prevention and treatment. Dengvaxia is an effective vaccine that prevents dengue by stimulating the immune system to produce protective responses against the virus, reducing the risk of infection and severe complications, and improving public health outcomes in endemic areas. For example, in June 2024, the Centers for Disease Control and Prevention (CDC) reported that the Americas had over 9.7 million dengue cases in 2024, double the 4.6 million cases in 2023. Puerto Rico declared a public health emergency with 1,498 cases, and 745 cases were reported among U.S. travelers. As a result, the high incidence of dengue is propelling the growth of the dengvaxia market.
The rise in international travel is expected to fuel the growth of the dengvaxia market. International travel, which includes tourism, business, and education, increases the risk of spreading infectious diseases such as dengue. This heightened risk drives the demand for preventive measures such as vaccines. Dengvaxia helps protect travelers from contracting dengue in endemic areas and reduces the risk of disease transmission across borders. For instance, in May 2024, the Office for National Statistics reported a significant increase in the number of international visits to the UK, rising from 31.2 million in 2022 to 38 million in 2023. As a result, the growth in international travel will contribute to the expansion of the dengvaxia market.
The rising healthcare expenditures are expected to further accelerate the growth of the dengvaxia market. Healthcare expenditures refer to the financial resources allocated by governments, private entities, or individuals for healthcare services, medical treatments, and health-related activities. The growth in healthcare expenditures is driven by factors such as the increasing demand for medical services, advancements in healthcare technology, and the rising prevalence of chronic diseases, leading to greater investment in healthcare infrastructure and treatments. The expenditure on Dengvaxia focuses on prevention, aiming to reduce the long-term costs of treating dengue and managing outbreaks. For example, in May 2024, the Office for National Statistics reported a 5.6% increase in nominal healthcare expenditure from 2022 to 2023, marking a significant acceleration compared to the 0.9% growth in 2022. Therefore, rising healthcare expenditures will further stimulate the growth of the dengvaxia market.
The key company operating in the dengvaxia market is Sanofi Pasteur Inc.
Asia-Pacific was the largest region in the dengvaxia market in 2024. Latin America is expected to be the fastest-growing region in the forecast period. The regions covered in dengvaxia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dengvaxia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Dengvaxia is a recombinant vaccine designed to protect against dengue fever, a viral disease transmitted by Aedes mosquitoes. It works by stimulating the immune system to generate a targeted response, preventing infection and reducing the risk of severe complications. This vaccine plays a key role in public health efforts in areas where dengue is endemic.
The main category of dengvaxia includes the vaccine itself and other related options. Dengvaxia is the first vaccine specifically developed to prevent dengue fever. It aims to provide immunity against the virus that causes the disease, helping to lessen the severity and frequency of dengue outbreaks. As an essential tool in regions prone to dengue, it has been used in various countries to protect at-risk populations. Dengvaxia is distributed through hospitals, clinics, and public health programs, and is administered for multiple purposes, such as preventing the disease in individuals with prior exposure, offering protection in high-risk areas, immunizing travelers, and supporting pediatric and adolescent vaccination.
The dengvaxia market research report is one of a series of new reports that provides dengvaxia market statistics, including dengvaxia industry global market size, regional shares, competitors with a dengvaxia market share, detailed dengvaxia market segments, market trends and opportunities, and any further data you may need to thrive in the dengvaxia industry. This dengvaxia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The dengvaxia market consists of sales of dengvaxia (CYD-TDV), disposable syringes and needles, pre-filled syringes of dengvaxia, and unit-dose packaging. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Dengvaxia Market Characteristics4. Dengvaxia Market Trends and Strategies5. Dengvaxia Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Dengvaxia Pricing Analysis & Forecasts30. Global Dengvaxia Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Dengvaxia Market32. Recent Developments in the Dengvaxia Market
3. Dengvaxia Market Biologic Drug Characteristics
6. Global Dengvaxia Growth Analysis and Strategic Analysis Framework
8. Dengvaxia Market Segmentation
9. Global Dengvaxia Epidemiology of Clinical Indications
10. Dengvaxia Market Regional and Country Analysis
11. Asia-Pacific Dengvaxia Market
12. China Dengvaxia Market
13. India Dengvaxia Market
14. Japan Dengvaxia Market
15. Australia Dengvaxia Market
16. South Korea Dengvaxia Market
17. Western Europe Dengvaxia Market
18. UK Dengvaxia Market
19. Germany Dengvaxia Market
20. France Dengvaxia Market
21. Eastern Europe Dengvaxia Market
22. North America Dengvaxia Market
23. USA Dengvaxia Market
24. Canada Dengvaxia Market
25. South America Dengvaxia Market
26. Middle East Dengvaxia Market
27. Africa Dengvaxia Market
28. Dengvaxia Market Competitive Landscape and Company Profiles
29. Global Dengvaxia Market Pipeline Analysis
33. Dengvaxia Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Dengvaxia Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on dengvaxia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for dengvaxia? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dengvaxia market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Type: Dengvaxia; Other Types2) by Distribution Channel: Hospitals; Clinics; Public Health Programs
3) by Clinical Indication: Prevention in Previously Infected Individuals; Protection in High-Risk Regions; Traveler Immunization; Pediatric and Adolescent Use
Key Companies Mentioned: Sanofi Pasteur Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Sanofi Pasteur Inc.
